Caricamento...
A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor associated with adverse events and public health concerns which have diminished its place in clinical practice, particularly in resource-rich settings. While international guidelines do not contain ddI-containing regimens in preferred...
Salvato in:
| Pubblicato in: | Int J STD AIDS |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4677683/ https://ncbi.nlm.nih.gov/pubmed/25281538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0956462414554433 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|